Recently, aberrant expression of lncH19 has been associated with circulating IL-6 or IL-8 levels and poor prognosis for MM patients [21]; moreover, Pan et al. proposed the upregulation of serum lncRNAH19 as a novel biomarker for early diagnosis and clinical treatment of MM [22]. The gene discussed is CXCL8; the disease is Miyoshi myopathy.